cardiol therapeutics is a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure. heart failure is a chronic condition that affects more than 26 million people globally. over five million adults in the u.s. suffer from heart failure, and it remains a leading cause of death and hospitalization with associated healthcare costs exceeding $30 billion annually. people with heart failure experience shortness of breath, fatigue, rapid heart rate, edema, reduced exercise capacity and a marked reduction in quality of life. approximately half of all heart failure patients have heart failure with preserved ejection fraction (hfpef), which is often associated with diabetes, obesity and high blood pressure and for which there have been no new therapies developed in over 20 years. cardiol is developing ctx01, a proprietary nanoformulation of pharmaceutical cannabidiol for the treatment of hfpef. cannabidiol has
Company profile
Ticker
CRDL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CRDL stock data
Latest filings (excl ownership)
6-K
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
2 Apr 24
20-F
2023 FY
Annual report (foreign)
1 Apr 24
6-K
Material Change Report
26 Feb 24
6-K
Cardiol Therapeutics Completes Patient Enrollment in its Phase II
21 Feb 24
6-K
Cardiol Therapeutics Granted Orphan Drug Designation for its
15 Feb 24
6-K
Current report (foreign)
24 Jan 24
6-K
Cardiol Therapeutics Announces it has Exceeded
9 Jan 24
6-K
MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patient Recruitment during Q1 2024
5 Dec 23
6-K
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group
16 Nov 23
6-K
Current report (foreign)
14 Nov 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
9.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 6 |
Closed positions | 7 |
Increased positions | 4 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 5.88 bn |
Total shares | 6.68 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MMCAP International Inc. SPC | 2.95 mm | $2.63 bn |
AXS Investments | 1.30 mm | $1.16 bn |
AdvisorShares Investments | 1.22 mm | $1.09 bn |
Tejara Capital | 497.06 k | $442.38 mm |
BMO Bank of Montreal | 112.18 k | $110.07 mm |
We Are One Seven | 100.00 k | $89.00 mm |
Cambridge Investment Research Advisors | 76.61 k | $68.00 k |
Advisor | 66.80 k | $59.45 mm |
Laird Norton Trust | 61.33 k | $54.58 mm |
Geode Capital Management | 52.44 k | $46.67 mm |
Press releases
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
2 Apr 24
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?
5 Mar 24
Thinking about buying stock in MicroCloud Hologram, CleanSpark, Cardiol Therapeutics, Atlasclear Holdings, or EZCORP?
26 Feb 24
Thinking about buying stock in C4 Therapeutics, Safety Shot, Intuitive Machines, Cardiol Therapeutics, or Iovance Biotherapeutics?
21 Feb 24
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
21 Feb 24